ClinicalTrials.gg
CompletedNCT02631876FORWARD IUpdated Oct 14, 2020Results posted

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

A Phase 3 interventional study of Mirvetuximab soravtansine and Paclitaxel in Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma and Fallopian Tube Cancer, sponsored by ImmunoGen, Inc.. Completed at 131 sites in 13 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-14.

Sponsored by ImmunoGen, Inc. (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies testing paclitaxel in Carcinoma, Ovarian Epithelial — 2 open to participants now, 3 under way, 1 of them phase 3. Paclitaxel · Carcinoma, Ovarian Epithelial.

Enrollment
12th of 60
366 · median 47
Started
2016
the only one that year
Phase 3
17 of 71
1 open now
Registered
65th of 71
by date

Among the 71 studies testing paclitaxel in Carcinoma, Ovarian Epithelial, this one is the 12th largest by enrollment of the 60 interventional ones that give a count, is the only one that started in 2016, is one of 17 in phase 3, and was the 65th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

2 of the 71 studies testing paclitaxel in Carcinoma, Ovarian Epithelial are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies testing paclitaxel in Carcinoma, Ovarian Epithelial, or all of them as a file.
02

Study summary

This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.

Read the detailed description

Participants will be randomized to either mirvetuximab soravtansine or investigator's choice chemotherapy.

03

Conditions studied

  • Epithelial Ovarian Cancer
  • Primary Peritoneal Carcinoma
  • Fallopian Tube Cancer
  • Ovarian Cancer

Keywords

  • Epithelial ovarian cancer
  • Fallopian tube cancer
  • Primary peritoneal cancer
  • IMGN853
  • ADC
  • Antibody drug conjugate
  • ImmunoGen
  • Antibody
  • Folate receptor alpha
  • mirvetuximab soravtansine
  • Phase 3
  • platinum-resistant
  • MIRV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer
  • Participants must have folate receptor alpha positive tumor expression as defined in the protocol
  • Participants must have platinum-resistant ovarian cancer, defined as progression within 6 months from completion of a minimum of four cycles of platinum-containing therapy.
  • Participants must have received at least one but no more than three prior systemic treatment regimens and for whom single-agent chemotherapy is appropriate as the next
  • Participants must have at least one lesion that meets the definition of by 1.1

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of clear cell, low grade ovarian cancer or mixed tumors
  • Participants with primary platinum- disease
  • Serious concurrent illness or active infection as defined in the protocol
  • Prior treatment with mirvetuximab soravtansine
  • Women who are pregnant or breast feeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    Mirvetuximab Soravtansine

    Participants will receive mirvetuximab soravtansine at 6 milligrams/kilogram (mg/kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of a 3 week cycle. Participants will continue to receive study drug until they experience progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (as assessed by the blinded independent review committee \[BIRC\]), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 86.9 weeks)

    Drug: Mirvetuximab soravtansine

  • Experimental
    Investigator's Choice (IC) Chemotherapy

    Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel will be administered at 80 milligrams/square meter (mg/m\^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan will be administered at 4 mg/m\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin will be administered at 40 mg/m\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion. Participants will continue to receive study drug until they experience PD per RECIST version 1.1 (as assessed by BIRC), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 62.9 weeks)

    Drug: Paclitaxel · Drug: Pegylated liposomal doxorubicin · Drug: Topotecan

Interventions

  • Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.

  • Paclitaxel will be administered per dose and schedule specified in the arm.

  • Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.

  • Topotecan will be administered per dose and schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the Study

    PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the sum of the longest diameters (SoD) of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)

  2. PFS, as Assessed by BIRC Per RECIST Version 1.1 in Participants With High Folate Receptor Alpha Level (≥ 75% of Tumor Staining)

    PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)

Secondary outcomes

  1. Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by BIRC Per RECIST1.1

    ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the SoD of target lesions, taking as reference the baseline SoD.

    Time frame: From randomization until first BOR of CR or PR (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)

  2. Overall Survival (OS)

    OS was defined as the time from the date of randomization until the date of death from any cause. Participants who did not experience the event of death were censored at their last date known to be alive. OS was estimated using the Kaplan-Meier method.

    Time frame: From the date of randomization until the time of death (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)

  3. Number of Participants Achieving at Least a 15% (≥ 15-Point) Absolute Improvement From Baseline on the EORTC QLQ-OV28 Abdominal/Gastrointestinal (AB/GI) Symptom Subscale at Week 8/9 Assessment

    European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer 28 (EORTC QLQ-OV28) is a 28-item ovarian cancer supplemental module. It comprises of 6 symptom scales (AB/GI symptoms, peripheral neuropathy, other chemotherapy side-effects, hormonal symptoms, body image, attitude to disease, treatment), and sexual functioning. Participants were asked to indicate extent to which they experienced AB/GI symptoms. Participants responded on a scale of 1-4(1=not at all, 2=a little, 3=quite a bit, 4=very much) to following: Did you have abdominal pain? Did you have a bloated feeling in your abdomen? Did you have problems with your clothes feeling too tight? Did you experience any change in bowel habit as a result of your disease or treatment? Were you troubled by passing wind/gas/flatulence? Have you felt full too quickly after beginning to eat? Have you had indigestion/heartburn? Data were transformed to a scale from 0-100. Lower scores=better health.

    Time frame: Baseline, Week 8/9

  4. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Adverse event (AE): any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. Severity: graded per National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) v4.03 on following scale: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Relation of AE to treatment was determined by investigator. Serious AEs: death, life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent/significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs: any AE that emerged on or after the first dose, and within 30 days of the last dose. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported AEs module.

    Time frame: From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)

  5. Gynecologic Cancer Intergroup (GCIG) CA-125 Response Rate: Percentage of Participants With GCIG CA-125 Confirmed Clinical Responses

    CA-125 Response rate wasdefined as the number of participants with a CA-125 confirmed response divided by the number of participants in the CA-125 response-evaluable population multiplied by 100.

    Time frame: From first dose of study drug until CA-125 response (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)

  6. PFS, as Assessed by Investigator Per RECIST Version 1.1

    PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)

  7. Duration of Response (DOR), as Assessed by BIRC Per RECIST v1.1

    DOR was defined as the time from the date of the first response (CR or PR), whichever was recorded first, until the date of PD. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was only defined for participants who had a BOR of CR or PR using the method of Kaplan-Meier.

    Time frame: From the date of first response (CR or PR) until the date of PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)

  8. Area Under the Plasma Concentration-Versus Time Curve From Time of Dose Until Tlast (AUClast) of Mirvetuximab Soravtansine,Total M9346A Antibody, DM4, and S-methyl DM4

    PK parameters were calculated using standard non-compartmental methods.

    Time frame: Pre-dose and within 5 minutes after mirvetuximab soravtansine infusion on Day 1 of Cycles 1 and 3; and Day 8 and 15 of Cycles 1 and 3

  9. Number of Participants With Anti-Drug Antibodies (ADA)

    An electrochemiluminescent method was used for the detection of anti-mirvetuximab soravtansine antibodies in plasma from samples collected in dipotassium ethylenediaminetetraacetic acid (K2EDTA) tubes. The qualitative assay was designed to detect anti-mirvetuximab soravtansine antibodies in human plasma.

    Time frame: Pre-dose and within 5 minutes after mirvetuximab soravtansine infusion on Day 1 of Cycles 1, 2, and 4; pre-dose on Day 1 of Cycle 6

07

Results

Posted Jun 9, 2020

Participant flow

Participant flow — Overall Study
MilestoneMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Started248118
Safety population243109
Completed12955
Not completed11963
Withdrew: Death9650
Withdrew: Investigator's discretion10
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject169
Withdrew: Other than specified44

Outcome measures

PrimaryProgression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the Study

PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the sum of the longest diameters (SoD) of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Reported as:
Median · months
Progression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the Study
monthsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Progression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the Study4.14 (3.75 to 4.53)4.44 (2.83 to 5.59)
PrimaryPFS, as Assessed by BIRC Per RECIST Version 1.1 in Participants With High Folate Receptor Alpha Level (≥ 75% of Tumor Staining)

PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Reported as:
Median · months
PFS, as Assessed by BIRC Per RECIST Version 1.1 in Participants With High Folate Receptor Alpha Level (≥ 75% of Tumor Staining)
monthsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
PFS, as Assessed by BIRC Per RECIST Version 1.1 in Participants With High Folate Receptor Alpha Level (≥ 75% of Tumor Staining)4.76 (4.11 to 5.68)3.25 (1.97 to 5.59)
SecondaryObjective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by BIRC Per RECIST1.1

ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the SoD of target lesions, taking as reference the baseline SoD.

Time frame:
From randomization until first BOR of CR or PR (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by BIRC Per RECIST1.1
percentage of participantsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by BIRC Per RECIST1.122 (17.2 to 27.9)12 (6.6 to 19.1)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization until the date of death from any cause. Participants who did not experience the event of death were censored at their last date known to be alive. OS was estimated using the Kaplan-Meier method.

Time frame:
From the date of randomization until the time of death (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Reported as:
Median · months
Overall Survival (OS)
monthsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Overall Survival (OS)15.57 (12.85 to 18.04)13.93 (11.40 to 18.50)
SecondaryNumber of Participants Achieving at Least a 15% (≥ 15-Point) Absolute Improvement From Baseline on the EORTC QLQ-OV28 Abdominal/Gastrointestinal (AB/GI) Symptom Subscale at Week 8/9 Assessment

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer 28 (EORTC QLQ-OV28) is a 28-item ovarian cancer supplemental module. It comprises of 6 symptom scales (AB/GI symptoms, peripheral neuropathy, other chemotherapy side-effects, hormonal symptoms, body image, attitude to disease, treatment), and sexual functioning. Participants were asked to indicate extent to which they experienced AB/GI symptoms. Participants responded on a scale of 1-4(1=not at all, 2=a little, 3=quite a bit, 4=very much) to following: Did you have abdominal pain? Did you have a bloated feeling in your abdomen? Did you have problems with your clothes feeling too tight? Did you experience any change in bowel habit as a result of your disease or treatment? Were you troubled by passing wind/gas/flatulence? Have you felt full too quickly after beginning to eat? Have you had indigestion/heartburn? Data were transformed to a scale from 0-100. Lower scores=better health.

Time frame:
Baseline, Week 8/9
Reported as:
Count of participants · Participants
Number of Participants Achieving at Least a 15% (≥ 15-Point) Absolute Improvement From Baseline on the EORTC QLQ-OV28 Abdominal/Gastrointestinal (AB/GI) Symptom Subscale at Week 8/9 Assessment
ParticipantsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Number of Participants Achieving at Least a 15% (≥ 15-Point) Absolute Improvement From Baseline on the EORTC QLQ-OV28 Abdominal/Gastrointestinal (AB/GI) Symptom Subscale at Week 8/9 Assessment457
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

Adverse event (AE): any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. Severity: graded per National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) v4.03 on following scale: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Relation of AE to treatment was determined by investigator. Serious AEs: death, life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent/significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs: any AE that emerged on or after the first dose, and within 30 days of the last dose. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported AEs module.

Time frame:
From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)242107
SecondaryGynecologic Cancer Intergroup (GCIG) CA-125 Response Rate: Percentage of Participants With GCIG CA-125 Confirmed Clinical Responses

CA-125 Response rate wasdefined as the number of participants with a CA-125 confirmed response divided by the number of participants in the CA-125 response-evaluable population multiplied by 100.

Time frame:
From first dose of study drug until CA-125 response (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Reported as:
Number · percentage of participants
Gynecologic Cancer Intergroup (GCIG) CA-125 Response Rate: Percentage of Participants With GCIG CA-125 Confirmed Clinical Responses
percentage of participantsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Gynecologic Cancer Intergroup (GCIG) CA-125 Response Rate: Percentage of Participants With GCIG CA-125 Confirmed Clinical Responses51 (44.1 to 58.3)27 (17.6 to 37.8)
SecondaryPFS, as Assessed by Investigator Per RECIST Version 1.1

PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Reported as:
Median · months
PFS, as Assessed by Investigator Per RECIST Version 1.1
monthsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
PFS, as Assessed by Investigator Per RECIST Version 1.14.27 (4.11 to 5.06)4.24 (2.76 to 5.36)
SecondaryDuration of Response (DOR), as Assessed by BIRC Per RECIST v1.1

DOR was defined as the time from the date of the first response (CR or PR), whichever was recorded first, until the date of PD. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was only defined for participants who had a BOR of CR or PR using the method of Kaplan-Meier.

Time frame:
From the date of first response (CR or PR) until the date of PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Reported as:
Median · months
Duration of Response (DOR), as Assessed by BIRC Per RECIST v1.1
monthsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Duration of Response (DOR), as Assessed by BIRC Per RECIST v1.15.65 (4.17 to 8.51)7.26 (4.14 to NA)
SecondaryArea Under the Plasma Concentration-Versus Time Curve From Time of Dose Until Tlast (AUClast) of Mirvetuximab Soravtansine,Total M9346A Antibody, DM4, and S-methyl DM4

PK parameters were calculated using standard non-compartmental methods.

Time frame:
Pre-dose and within 5 minutes after mirvetuximab soravtansine infusion on Day 1 of Cycles 1 and 3; and Day 8 and 15 of Cycles 1 and 3
Reported as:
Mean · hours*milligrams/milliliter (hr*mg/mL)
Area Under the Plasma Concentration-Versus Time Curve From Time of Dose Until Tlast (AUClast) of Mirvetuximab Soravtansine,Total M9346A Antibody, DM4, and S-methyl DM4
hours*milligrams/milliliter (hr*mg/mL)Mirvetuximab Soravtansine
Mirvetuximab Soravtansine at Cycle 120.53 ± 10.31
Mirvetuximab Soravtansine at Cycle 322.40 ± 7.770
Total M9346A antibody at Cycle 123.23 ± 9.463
Total M9346A antibody at Cycle 331.20 ± 11.52
DM4 at Cycle 1348.5 ± 265.7
DM4 at Cycle 3347.4 ± 280.9
S-methyl DM4 at Cycle 11586 ± 1496
S-methyl DM4 at Cycle 31512 ± 1278
SecondaryNumber of Participants With Anti-Drug Antibodies (ADA)

An electrochemiluminescent method was used for the detection of anti-mirvetuximab soravtansine antibodies in plasma from samples collected in dipotassium ethylenediaminetetraacetic acid (K2EDTA) tubes. The qualitative assay was designed to detect anti-mirvetuximab soravtansine antibodies in human plasma.

Time frame:
Pre-dose and within 5 minutes after mirvetuximab soravtansine infusion on Day 1 of Cycles 1, 2, and 4; pre-dose on Day 1 of Cycle 6
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADA)
ParticipantsMirvetuximab Soravtansine
Number of Participants With Anti-Drug Antibodies (ADA)13

Adverse events

Collected over From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mirvetuximab Soravtansine96/243 (39.5%)67/243 (27.6%)242/243 (99.6%)
Investigator's Choice (IC) Chemotherapy50/109 (45.9%)31/109 (28.4%)106/109 (97.2%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Intestinal obstructionGastrointestinal disorders10/2433/109
Small intestinal obstructionGastrointestinal disorders5/2434/109
PneumonitisRespiratory, thoracic and mediastinal disorders7/2432/109
Pleural effusionRespiratory, thoracic and mediastinal disorders5/2433/109
SepsisInfections and infestations3/2433/109
PyrexiaGeneral disorders0/2433/109
Large intestinal obstructionGastrointestinal disorders4/2432/109
Abdominal painGastrointestinal disorders2/2432/109
VomitingGastrointestinal disorders2/2432/109
AscitesGastrointestinal disorders1/2432/109
Most frequent other events
Showing 10 of 533
Most frequent other events
EventMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
NauseaGastrointestinal disorders131/24346/109
DiarrhoeaGastrointestinal disorders107/24318/109
Vision blurredEye disorders104/2436/109
NeutropeniaBlood and lymphatic system disorders16/24343/109
FatigueGeneral disorders83/24338/109
Abdominal painGastrointestinal disorders80/24323/109
KeratopathyEye disorders77/2431/109
AnaemiaBlood and lymphatic system disorders34/24332/109
ConstipationGastrointestinal disorders64/24331/109
Dry eyeEye disorders68/2432/109

Baseline characteristics

ITT population included all participants randomized in the study.

Age, Continuous
Age, Continuous(years)Mirvetuximab SoravtansineInvestigator's Choice (IC) ChemotherapyTotal
Mean62.7 ± 10.2962.9 ± 10.5162.8 ± 10.35
Sex: Female, Male
Sex: Female, Male(Participants)Mirvetuximab SoravtansineInvestigator's Choice (IC) ChemotherapyTotal
Female248118366
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Mirvetuximab SoravtansineInvestigator's Choice (IC) ChemotherapyTotal
Hispanic or Latino12921
Not Hispanic or Latino225102327
Unknown or Not Reported11718
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mirvetuximab SoravtansineInvestigator's Choice (IC) ChemotherapyTotal
American Indian or Alaska Native011
Asian628
Native Hawaiian or Other Pacific Islander000
Black or African American7310
White225105330
More than one race224
Unknown or Not Reported8513
08

Study locations

131 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Arizona Oncology Associates, PC - HAL
    Tempe, Arizona 85284, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85711, United States
  • UCLA Women's Health Clinical Research Unit - OBGYN
    Los Angeles, California 90095, United States
  • University of California San Diego Medical Center
    San Diego, California 92093, United States
  • California Pacific Medical Center
    San Francisco, California 94118, United States
  • Kaiser Permanente Medical Center
    Vallejo, California 94589, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Norwalk Hospital/WCHN
    Norwalk, Connecticut 06856, United States
  • Florida State University College of Medicine
    Sarasota, Florida 34239, United States
  • Georgia Regents University (GRU)-Medical College of Georgia (MCG) - Cancer Center
    Augusta, Georgia 30912, United States
  • Rush University Medical Center
    Chicago, Illinois 60629, United States
  • Sudarshan Sharma LTD
    Hinsdale, Illinois 60521, United States
  • Community Health Network, Inc.
    Indianapolis, Indiana 46184, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40241, United States
  • Women's Cancer Care
    Covington, Louisiana 70433, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • WK Physician Network Clinical Research
    Shreveport, Louisiana 71101, United States
  • Holy Cross Hospital
    Silver Spring, Maryland 20902, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Massachusetts Memorial Medical Center
    Worcester, Massachusetts 01605, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Mercy Women's Oncology
    Springfield, Missouri 65804, United States
  • Center of Hope
    Reno, Nevada 89502, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • MD Anderson Cancer Center - Cooper Health
    Camden, New Jersey 08103, United States
  • Overlook Medical Center
    Summit, New Jersey 07901, United States
  • The University of New Mexico Comprehensive Cancer Center - Memorial Medical Center
    Albuquerque, New Mexico 87131, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Memorial Sloan Kettering Cancer Center and (MSK Monmouth) and ( MSK Westchester)
    New York, New York 10065, United States
  • Levine Cancer Institute - Carolinas Medical Center
    Charlotte, North Carolina 28204, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45267, United States
  • Fairview Hospital, Moll Pavilion Cancer Center
    Cleveland, Ohio 44111, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • OSU Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Hillcrest Hospital
    Mayfield, Ohio 44124, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Oklahoma Cancer Specialists and Research Institute, LLC
    Tulsa, Oklahoma 74146, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Magee - Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Women & Infants of Rhode Island
    Providence, Rhode Island 02905, United States
  • Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Texas Oncology-Austin Central
    Austin, Texas 78731, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Texas Oncology - Fort Worth
    Fort Worth, Texas 76104, United States
  • Texas Oncology - The Woodlands, Gynecologic Oncology
    The Woodlands, Texas 77380, United States
  • Texas Oncology-Tyler
    Tyler, Texas 75702, United States
  • Kadlec Clinic Hematology & Oncology
    Kennewick, Washington 99336, United States
  • Froedtert and Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • AZ Groeninge - Oncology Centre
    Kortrijk, 8500, Belgium
  • Universitaire Ziekenhuizen (UZ) Leuven-Gasthuisberg
    Leuven, B-3000, Belgium
  • Centre Hospitalier de l'Ardenne
    Libramont, 6800, Belgium
  • University Clinical Center of Republic of Srpska
    Banja Luka, 78 000, Bosnia and Herzegovina
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • London Health Sciences Centre
    London, Ontario N6A 4L6, Canada
  • The Ottawa Hospital Cancer Centre
    Ottawa, Ontario K1H8L6, Canada
  • Sunnybrook Research Institute - Odette Cancer Centre
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • Hopital de la CitedelaSante
    Laval, Quebec H7M 3L9, Canada
  • Centre hospitalier de l'Université de Montréal
    Montreal, Quebec H2X 0A9, Canada
  • McGill University Health Centre - Glen Site
    Montréal, Quebec H4A 3J1, Canada
  • Porodnicka A Gynekologicka Klinika
    Hradec Králové, 500 05, Czechia
  • University Hospital Ostrava
    Ostrava Poruba, 708 52, Czechia
  • Onkologicke oddeleni Krajske nemocnice T. Bati, a.s., Zlin
    Zlín, 76275, Czechia
  • Institut de Cancerologie de L'Ouest - site Paul Papin
    Angers, 49055, France
  • CHRU Jean Minjoz
    Besançon, 25030, France
  • Institut Bergonie
    Bordeaux, 33076, France
  • Cochin Hospital
    Paris, 75014, France
  • Hôpital Croix St-Simon
    Paris, 75020, France
  • Centre Hospitalier Lyon-Sud
    Pierre-Bénite, 69495, France
  • Centre Armoricain de radiotherapie, Imagerie Medicale et Oncol
    Plérin, 22190, France
  • Centre Eugene Marquis
    Rennes, 35042, France
  • Institut Curie-Hopital Rene Huguenin
    Saint-Cloud, 92210, France
  • Institut Claudius Regaud
    Toulouse, 31059, France
  • Institut de Cancerologie de Lorraine
    Vandœuvre-lès-Nancy, 54519, France
  • Gustave Roussy Institution
    Villejuif, 94800, France
  • Bon Secours Hospital
    Cork, Ireland
  • Mater Private Hospital and Mater Misericordiae University Hospital
    Dublin, Ireland
  • Istituto Europeo di Oncologia
    Milano, MI 20141, Italy
  • Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
    Bologna, 40138, Italy
  • Azienda Sanitaria Locale (ASL)
    Brindisi, 72100, Italy
  • Azienda Unita Sanitaria Locale di Ravenna
    Faenza, 48018, Italy
  • Romagnolo per lo Studio e la Cura dei Tumori IRST-IRCCS - Oncologia medica
    Meldola (FC), 47014, Italy
  • Ospedale San Raffaele
    Milan, 20132, Italy
  • Fondazione IRCCS National Cancer Institute
    Milan, 20133, Italy
  • Istituto Nazionale Tumori- G. Pascale
    Naples, 80131, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • LLC "VitaMed"
    Moscow, 121309, Russian Federation
  • State Budget-Funded Healthcare Institution of Novosibirsk Oblast "Novosibirsk Oblast Oncology Dispensary"
    Novosibirsk, 630108, Russian Federation
  • Budget-Funded Healthcare Institution of Omsk Oblast "Clinical Oncology Dispensary"
    Omsk, 644013, Russian Federation
  • State Budget Institution of Health "Leningrad Regional Oncologicacal Dispensary"
    Saint Petersburg, 191014, Russian Federation
  • Oncology and Radiology Institute Serbia
    Belgrade, 11 000, Serbia
  • Clinical Centre Nis, Oncology Clinic
    Niš, 18 000, Serbia

Showing the first 100 of 131 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 Jun;32(6):757-765. doi: 10.1016/j.annonc.2021.02.017. Epub 2021 Mar 2. PubMed 33667670 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Jan 2019, 34 months.

Results were first posted in Jun 2020, 1 year 5 months after primary completion.

Of 33 phase 3 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2015
First posted
Dec 16, 2015
StartActual
Mar 2, 2016
Primary completionActual
Jan 2019
CompletionActual
Jan 2020
Results first posted
Jun 9, 2020
Last update
Oct 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02631876
Lead sponsor
ImmunoGen, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2015
Start date
Mar 2, 2016
Primary completion
Jan 2019
Completion
Jan 2020
Results posted
Jun 9, 2020
Last update
Oct 14, 2020

Study contacts

CMO ImmunoGen
study director · ImmunoGen, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mirvetuximab soravtansine · Paclitaxel · Liposomal doxorubicin · Topotecan

Start the discussion